Premium
Inhibitory Effect of KWD 2131, Terbutaline, and DSCG on the Immediate and Late Allergen‐Induced Bronchoconstriction
Author(s) -
Hegardt B.,
Pauwels R.,
Straeten M.
Publication year - 1981
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/j.1398-9995.1981.tb04105.x
Subject(s) - bronchoconstriction , allergen , terbutaline , medicine , immunology , provocation test , inhibitory postsynaptic potential , asthma , allergy , pathology , alternative medicine
β‐adrenoceptor stimulants exhibit both bronchodilating and anti‐allergic activities. KWD 2131 is a new β‐agonist with preferably anti allergic property. In an earlier study, nebulized KWD 2131 in a non‐bronchodilating dose (0.25 ‐ 0.50 mg) did not give significant protection against immediate reaction. The present study evaluated whether an increased nebulized dose of the new compound (5 mg) could protect against either immediate and/or late responses. The response was compared with a nebulized dose of terbutaline (5 mg) and with twice the recommended dose DSCG (40 mg). The study included 10 patients with known allergic asthma. It was designed as a single‐blind cross‐over trial with randomized allocation of the drugs. Lung functions were measured spirometrically and by body‐plethysmograph; flow volume curves were drawn. KWD 2131 gave no significant protection against immediate reaction. Both terbutaline and DSCG did so, terbutaline being more efficient. Contrary to the β‐agonists, DSCG also gave protection against late response.